Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHA NYSE:ATNM NASDAQ:EPIX NASDAQ:GRCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$9.55+8.3%$8.43$0.23▼$8.36$37.67M2.79602,475 shs25,155 shsATNMActinium Pharmaceuticals$1.26+5.0%$1.15$0.95▼$1.95$37.65M-0.11161,762 shs131,972 shsEPIXESSA Pharma$0.20$0.20$0.18▼$1.94$9.52M1.573.75 million shsN/AGRCEGrace Therapeutics$2.33-1.3%$3.97$1.79▼$5.18$36.52M0.321.42 million shs297,327 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma+8.28%+14.65%-15.86%+105.38%+242.29%ATNMActinium Pharmaceuticals+11.50%+5.88%+28.52%+8.62%-16.00%EPIXESSA Pharma0.00%0.00%0.00%0.00%-88.23%GRCEGrace Therapeutics-0.43%+10.95%-54.58%-36.68%-22.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$9.55+8.3%$8.43$0.23▼$8.36$37.67M2.79602,475 shs25,155 shsATNMActinium Pharmaceuticals$1.26+5.0%$1.15$0.95▼$1.95$37.65M-0.11161,762 shs131,972 shsEPIXESSA Pharma$0.20$0.20$0.18▼$1.94$9.52M1.573.75 million shsN/AGRCEGrace Therapeutics$2.33-1.3%$3.97$1.79▼$5.18$36.52M0.321.42 million shs297,327 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma+8.28%+14.65%-15.86%+105.38%+242.29%ATNMActinium Pharmaceuticals+11.50%+5.88%+28.52%+8.62%-16.00%EPIXESSA Pharma0.00%0.00%0.00%0.00%-88.23%GRCEGrace Therapeutics-0.43%+10.95%-54.58%-36.68%-22.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 1.00Sell$4.00-58.12% DownsideATNMActinium Pharmaceuticals 3.00Buy$4.50257.14% UpsideEPIXESSA Pharma 1.00SellN/AN/AGRCEGrace Therapeutics 2.00Hold$6.00157.51% UpsideCurrent Analyst Ratings BreakdownLatest EPIX, ATHA, ATNM, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026ATNMActinium Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/AATNMActinium Pharmaceuticals$90K439.25N/AN/A$1.31 per share0.96EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%5/7/2026 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.08N/AN/AN/AN/A-100.85%-47.89%N/AEPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/AGRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)Latest EPIX, ATHA, ATNM, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ATHAAthira Pharma-$1.90N/AN/AN/AN/AN/A2/12/2026Q3 2026GRCEGrace Therapeutics-$0.09-$0.14-$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69839.96%N/AN/A N/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ALatest EPIX, ATHA, ATNM, and GRCE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A9.709.70ATNMActinium PharmaceuticalsN/A10.2510.25EPIXESSA PharmaN/A69.0669.06GRCEGrace TherapeuticsN/A14.9614.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%ATNMActinium Pharmaceuticals27.50%EPIXESSA Pharma75.12%GRCEGrace Therapeutics6.08%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma19.80%ATNMActinium Pharmaceuticals0.60%EPIXESSA Pharma15.50%GRCEGrace Therapeutics11.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma403.94 million3.16 millionNo DataATNMActinium Pharmaceuticals3031.38 million29.32 millionOptionableEPIXESSA Pharma5047.31 million39.98 millionOptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/AEPIX, ATHA, ATNM, and GRCE HeadlinesRecent News About These CompaniesGrace Therapeutics (GRCE) price target decreased by 47.83% to 6.12April 28, 2026 | msn.comGrace hit by CRL for GTx-104, shares plunge 45%April 25, 2026 | thepharmaletter.comTFDA declines Grace's stroke drug over manufacturing and packaging issues, shares slumpApril 25, 2026 | msn.comGrace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment ApplicationApril 23, 2026 | marketwatch.comFDA declines Grace's stroke drug over manufacturing and packaging issuesApril 23, 2026 | msn.comUS FDA declines to approve Grace Therapeutics' drug for a type of strokeApril 23, 2026 | reuters.comGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104April 23, 2026 | globenewswire.comGRCE stock in spotlight ahead of FDA verdict on brain bleed drug this weekApril 22, 2026 | msn.comGrace Therapeutics (NASDAQ:GRCE) Trading Up 1.9% - Should You Buy?April 16, 2026 | marketbeat.comGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026April 14, 2026 | globenewswire.comGrace Therapeutics Stock Short Interest Report | NASDAQ:GRCE | BenzingaApril 7, 2026 | benzinga.comWe're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn RateApril 4, 2026 | finance.yahoo.comGRCE Share News TodayApril 1, 2026 | uk.investing.comGrace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical ConferencesMarch 19, 2026 | globenewswire.comGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateFebruary 13, 2026 | finanznachrichten.deGrace: Fiscal Q3 Earnings SnapshotFebruary 12, 2026 | khou.comKGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateFebruary 12, 2026 | globenewswire.comGrace Therapeutics Enhances Executive Severance and Change‑in‑Control TermsJanuary 14, 2026 | theglobeandmail.comGrace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select ConferenceNovember 17, 2025 | globenewswire.comGrace Therapeutics Reports Q2 2026 Results and FDA ProgressNovember 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026Berkshire Bet Constellation Cuts Guidance: Why Shares Rose 8% By Leo Miller | April 10, 2026Domino's Pizza: Outlook for the Berkshire Holding After Q1 DropBy Leo Miller | April 29, 2026Berkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 20265 Baby Boomer Stock Favorites Now Trading at a DiscountBy Ryan Hasson | April 6, 2026EPIX, ATHA, ATNM, and GRCE Company DescriptionsAthira Pharma NASDAQ:ATHA$9.55 +0.73 (+8.28%) As of 05/4/2026Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Actinium Pharmaceuticals NYSE:ATNM$1.26 +0.06 (+5.00%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.29 +0.03 (+2.38%) As of 05/5/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.ESSA Pharma NASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Grace Therapeutics NASDAQ:GRCE$2.33 -0.03 (-1.27%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$2.33 +0.00 (+0.17%) As of 05/5/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
